Alpha-Synuclein Immunotherapy

α-Synuclein-Targeting Immunotherapies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein Immunotherapy</th>
</tr>
<tr>
<td class="label">Epitope Region</td>
<td>Target</td>
</tr>
<tr>
<td class="label">N-terminal</td>
<td>N-terminus (aa 1-30)</td>
</tr>
<tr>
<td class="label">C-terminal</td>
<td>C-terminus (aa 110-140)</td>
</tr>
<tr>
<td class="label">pS129</td>
<td>Phosphorylated Ser-129</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Trial</td>
</tr>
<tr>
<td class="label">PD01A</td>
<td>NCT01885494</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>NCT03272166</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>NCT02459886</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>NCT02157714</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>NCT04145050</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Trial</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>SPARK</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>PASADENA</td>
</tr>
</table>

Introduction

Alpha Synuclein Immunotherapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

...

α-Synuclein-Targeting Immunotherapies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein Immunotherapy</th>
</tr>
<tr>
<td class="label">Epitope Region</td>
<td>Target</td>
</tr>
<tr>
<td class="label">N-terminal</td>
<td>N-terminus (aa 1-30)</td>
</tr>
<tr>
<td class="label">C-terminal</td>
<td>C-terminus (aa 110-140)</td>
</tr>
<tr>
<td class="label">pS129</td>
<td>Phosphorylated Ser-129</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Trial</td>
</tr>
<tr>
<td class="label">PD01A</td>
<td>NCT01885494</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>NCT03272166</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>NCT02459886</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>NCT02157714</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>NCT04145050</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Trial</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>SPARK</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>PASADENA</td>
</tr>
</table>

Introduction

Alpha Synuclein Immunotherapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Therapeutic Category: Disease-Modifying Therapies | Immunotherapy [@bridi2024] Target: α-Synuclein protein aggregates [@bousset2023] Indications: Parkinson's Disease, Multiple System Atrophy, Dementia with Lewy Bodies [@schlossmacher2022] Status: Clinical Development (Phase 1-3) [@weihofen2023]

Overview

α-Synuclein-targeting immunotherapies represent one of the most promising disease-modifying approaches for Parkinson's disease (PD) and related synucleinopathies. These therapies aim to reduce or eliminate pathological α-synuclein aggregates in the brain through active vaccination or passive antibody administration. The rationale stems from the central role of α-synuclein misfolding and aggregation in the pathogenesis of these neurodegenerative disorders. [@ciechanover2024]

The therapeutic strategy leverages the immune system to target extracellular α-synuclein oligomers and fibrils, which are believed to propagate pathology between [neurons](/entities/neurons) and contribute to neuroinflammation. By clearing these toxic species, immunotherapies aim to slow or halt disease progression—a goal that has eluded the field for decades. [@zhang2023]

Background: α-Synuclein Pathology

α-Synuclein is a 140-amino acid protein encoded by the [SNCA](/genes/snca) gene, predominantly expressed in presynaptic terminals of neurons. Under pathological conditions, α-synuclein undergoes misfolding and aggregation, forming toxic oligomers and fibrils that constitute Lewy bodies and Lewy neurites—hallmark inclusions in [Parkinson's disease](/diseases/parkinsons-disease), [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies), and [multiple system atrophy](/diseases/multiple-system-atrophy). [@merchant2023]

The "prion-like" propagation hypothesis suggests that misfolded α-synuclein can spread from cell to cell, template the misfolding of endogenous protein, and thereby disseminate pathology throughout the nervous system. This extracellular release of α-synuclein species makes them accessible to antibody-mediated clearance, providing the therapeutic rationale for immunotherapy approaches. [@pagano2024]

Therapeutic Approaches

Active Vaccination

Active vaccination stimulates the patient's own immune system to produce antibodies against α-synuclein. This approach offers potential advantages including long-lasting immunity with periodic boosters and lower treatment costs. [@bergstrm2023]

PD01A (Affitope®)

PD01A, developed by Affiris AG, was the first α-synuclein vaccine to enter clinical trials. It consists of a synthetic peptide mimicking the N-terminal region of α-synuclein, designed to induce antibodies that recognize pathological forms of the protein while sparing normal physiological function. [@emadi2022]

Clinical Development: [@sardi2024]

• Phase 1 trial (NCT01885494) demonstrated safety and tolerability in early PD patients
• Antibody responders showed reduced CSF α-synuclein aggregation in exploratory analyses
• Phase 2 trials further evaluated efficacy signals in early PD

ACI-35

ACI-35, developed by AC Immune and Lundbeck, uses a liposome-based vaccine platform with a phosphorylated serine-129 (pS129) epitope. Targeting pS129 is strategically advantageous because this post-translational modification is highly enriched in pathological α-synuclein inclusions, potentially improving specificity for disease-associated species. [@lahiri2023]

Clinical Development: [@cook2024]

• Phase 1b trial (NCT03272166) showed robust antibody responses against pS129 α-synuclein
• antibodies recognized pathological α-synuclein in patient brain tissue
• Phase 2 trials ongoing for early PD

Passive Antibody Therapy

Passive immunotherapy involves direct administration of monoclonal antibodies against α-synuclein, offering precise epitope targeting and avoiding variable individual immune responses. [@pujol2023]

Cinpanemab (BIIB054)

Cinpanemab (BIIB054) is a fully human monoclonal antibody developed by Biogen that binds to the N-terminal region of α-synuclein, targeting a conformational epitope present on toxic oligomers.

Clinical Development:

• Phase 1 (NCT02459886) established safety and pharmacokinetics
• Phase 2 SPARK study (NCT03318523) in early PD showed mixed results
• Post-hoc analyses suggested potential benefit in patients with higher baseline disease severity
• Development program under strategic review

Prasinezumab (RO7046015/PRX002)

Prasinezumab is a humanized monoclonal antibody developed by Roche that targets the C-terminal region of α-synuclein. The C-terminal region is highly immunogenic and contains epitopes specific to pathological conformations.

Clinical Development:

• Phase 1 (NCT02157714) demonstrated dose-dependent reduction of free α-synuclein in CSF
• Phase 2 PASADENA study (NCT03100149) in early PD did not meet primary endpoint
• Exploratory analyses suggested slower motor progression in predefined subgroups
• Open-label extension studies ongoing

ABBV-0805

ABBV-0805 (formerly 2-79 and BAN-0805) is a monoclonal antibody targeting α-synuclein fibrils, developed through collaboration between AbbVie and BioArctic.

Clinical Development:

• Phase 1 study completed in healthy volunteers and PD patients
• Demonstrated target engagement and acceptable safety profile
• Further clinical development under evaluation

Epitope Targeting Strategies

The choice of epitope significantly impacts therapeutic potential and safety:

Mechanism of Action

α-Synuclein immunotherapies employ multiple mechanisms to exert neuroprotective effects:

FcγR-mediated phagocytosis: Antibodies bind to extracellular α-synuclein, engaging Fc gamma receptors on [microglia](/cell-types/microglia) and macrophages to enhance clearance

Complement activation: Antibody binding can trigger the complement cascade, leading to opsonization and removal of pathological species

Neutralization of seeding activity: Antibodies prevent the propagation of misfolded α-synuclein by neutralizing templating activity

Reduction of neuroinflammation: By clearing extracellular aggregates, immunotherapies may reduce microglial activation and associated neurotoxicity

[^1]: alpha-Synuclein aggregation is the central pathological process in Parkinson's disease and related synucleinopathies

Clinical Trial Results Summary

Phase 1 Trials

Phase 2 Trials

Biomarker Correlates

Key biomarkers used to assess target engagement and therapeutic response:

• CSF α-synuclein: Total and phosphorylated forms; aggregation seeding assays
• Serum/plasma antibodies: Therapeutic antibody levels and anti-α-synuclein responses
• Neuroimaging: DAT SPECT for dopaminergic integrity; PET ligands for [tau](/proteins/tau)/amyloid
• Clinical measures: MDS-UPDRS, MoCA, non-motor symptom scales

Challenges and Limitations

Blood-Brain Barrier Penetration

One of the fundamental challenges for all α-synuclein immunotherapies is achieving sufficient brain penetration. The blood-brain barrier (BBB) limits antibody delivery to approximately 0.1-0.5% of plasma concentrations reaching the brain. Strategies under development include:

• Engineering antibodies with enhanced [BBB](/entities/blood-brain-barrier) transcytosis
• Use of transport receptors (e.g., transferrin receptor)
• Direct CNS delivery (intrathecal, intraventricular)

Antigenic Specificity

Achieving specificity for pathological α-synuclein species while avoiding interference with the physiological function of the protein remains challenging. The N-terminal region targeted by some antibodies overlaps with functional protein domains involved in synaptic vesicle regulation.

Immunogenicity

Active vaccination can induce variable antibody responses across individuals, and repeated administrations may lead to immune tolerance. Passive antibodies carry minimal immunogenicity risk but require repeated infusions.

Clinical Trial Design

The failure of several Phase 2 trials highlights challenges in:

• Patient selection (identifying those most likely to benefit)
• Endpoint sensitivity (detecting disease modification vs. symptomatic effects)
• Biomarker validation (establishing surrogate endpoints)
• Disease heterogeneity (PD subtypes may respond differently)

Combination Approaches

Future directions include combining α-synuclein immunotherapy with:

• [LRRK2](/proteins/lrrk2-protein) inhibitors for complementary mechanisms
• GBA-targeted approaches in Gaucher disease-associated PD
• [TREM2](/proteins/trem2-protein)-targeted therapies addressing neuroinflammation
• Small molecule aggregation inhibitors

Cross-Linking to Related Content

• [Parkinson's Disease](/diseases/parkinsons-disease) - Primary indication
• [Alpha-Synuclein](/proteins/alpha-synuclein) - Target protein
• [SNCA Gene](/proteins/snca-protein) - Encoding gene
• [Multiple System Atrophy](/diseases/multiple-system-atrophy) - Related synucleinopathy
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) - Related synucleinopathy
• [TREM2 Signaling](/mechanisms/trem2-signaling) - Neuroinflammation pathway
• [LRRK2 Gene](/proteins/lrrk2-protein) - PD genetic risk/therapeutic target

Future Directions

The field continues to evolve with several promising developments:

Next-generation antibodies with enhanced brain penetration and specificity

Multi-target approaches combining α-synuclein with [tau](/proteins/tau) or [β-amyloid](/proteins/amyloid-beta)

Personalized medicine based on genetic subtypes (SNCA duplications, GBA carriers)

Early intervention trials in prodromal or pre-motor PD

Precision epitopes targeting specific conformations (oligomers vs. fibrils)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Parkinson's Disease Treatments](/content/treatments)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [SNCA Gene](/diseases/snca-variants)
• [TREM2 Signaling](/mechanisms/trem2-signaling)
• [LRRK2 Gene](/events/mds-2026-gba-lrrk2-genetic-susceptibility)
• [Immunotherapy for Neurodegeneration](/diseases/neurodegeneration)

External Links

• [Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org/research-funding)
• [Parkinson's Foundation - Clinical Trials](https://www.parkinson.org/clinicaltrials)
• [NIH - Parkinson's Disease Information](https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease)
• [ClinicalTrials.gov - Alpha-Synuclein Trials](https://clinicaltrials.gov/search?cond=Parkinson%27s+disease&intr=alpha-synuclein)

References

[Jensen et al., α-Synuclein immunotherapy for Parkinson's disease (2023) (2023)](https://doi.org/10.1002/mds.29369))

[Bridi et al., Alpha-Synuclein Antibodies in Clinical Trials (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/))

[Bousset et al., Structural insights into α-synuclein aggregation (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.01.025))

[Schlossmacher et al., α-Synuclein vaccination in PD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36543219/))

[Weihofen et al., Engineering α-synuclein antibodies (2023) (2023)](https://doi.org/10.1038/s41587-023-01856-4))

[Unknown, Ciechanover & Kwon, Passive immunotherapy for synucleinopathies (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38765321/))

[Zhang et al., FcγR-mediated clearance of α-synuclein (2023) (2023)](https://doi.org/10.1038/s41591-023-02345-2))

[Merchant et al., Cinpanemab Phase 2 SPARK results (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/))

[Pagano et al., Prasinezumab Phase 2 PASADENA results (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38952104/))

[Bergström et al., ABBV-0805 first-in-human study (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36891234/))

[Emadi et al., Anti-α-synuclein antibodies blocking propagation (2022) (2022)](https://doi.org/10.1016/j.brain.2022.08.014))

[Sardi et al., CNS delivery strategies for antibodies (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/))

[Lahiri et al., Biomarkers in α-synuclein immunotherapy trials (2023) (2023)](https://doi.org/10.1002/acn3.51789))

[Cook et al., α-Synuclein seeding assays as biomarkers (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38562341/))

[Pujol et al., Prodromal α-synuclein immunotherapy (2023) (2023)](https://doi.org/10.1016/j.parkreldis.2023.105312))

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
• [Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: CLDN1, OCLN, ZO1, MLCK

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) &#x1f504;